AI-Native Finance Back Office for Biotechnology: Production in 6-10 Weeks

Defensible delivery in a regulated environment

Internal audit teams in biotechnology are increasingly comfortable with AI in workflows, provided three conditions hold. The system is documented (model card, prompt repository, retrieval source list, threshold rationale). The decisions are traceable (audit log of inputs, outputs, model version, reviewer disposition). The controls are testable (the auditor can pull a random sample of cases and verify the workflow operated as documented). We engineer for all three from week one of Build because the alternative — retrofitting them into a working AI system — costs 4-6x as much and produces an inferior result.

Three regulatory pressures shape every biotechnology engagement we run on finance back office. The first is explainability — the regulator's right to receive a coherent rationale for any decision the workflow produced, in language a senior examiner understands. The second is replayability — the ability to reconstruct the inputs, model versions, and reasoning chain that led to that decision, six months or two years later. The third is segregation of duties — the line between automated action, drafted-with-review, and reserved-to-human steps, with no operator able to silently widen the automation envelope.

We address all three at the architecture level rather than as policy overlays. Explainability is wired into the prompt pipeline: every customer-facing output ships with the supporting source citations, the confidence band, and the policy clauses the model applied. Replayability is wired into the audit log: every inference call is stored with its full input context, model fingerprint, retrieval bundle, and downstream effects, with a retention policy aligned to the regulator's longest plausible review window. Segregation is wired into the reviewer UI: each step has a typed permission, each escalation has a named owner, each policy-edit action requires a second pair of eyes from a different team.

The practical effect for biotechnology leadership is that examinations stop feeling like archaeological digs. The supervisory question — "show me how this decision was made on date X" — becomes a one-query lookup in the audit log, returning the policy clauses, the source citations, the model version, the reviewer trail, and the downstream actions. The traditional posture would assemble that record over weeks; the AI-native posture assembles it on demand. That is the operational difference between a controlled AI workflow and a research prototype dressed in compliance language.

The single regulatory question that makes or breaks biotechnology finance back office engagements is "who is accountable for an automated decision". Our answer, baked into the architecture: there is always a named human owner per decision class, with the role visible in the reviewer interface, the audit log, and the governance map. Full automation does not mean no accountability — it means the named accountable human approved the policy that authorized the automation, and can revoke that authorization at any time without re-architecting the system.

From kickoff to thin-slice production

For biotechnology engagements on finance back office, the first 30 days are not about building features — they are about producing the labelled test set that will govern every subsequent decision. The test set is the most valuable artefact of the engagement, because it is what makes "did this change make the workflow better?" a measurable question instead of an opinion.

We spend week 1 on test-set capture. The operator team picks 200-400 representative cases spanning routine, exceptional, ambiguous, and adversarial. Each case has the expected outcome, the expected reasoning, and the source citations a reviewer would want to see. The test set is reviewed for coverage gaps, signed off by the engagement sponsor, and version-controlled alongside the prompts.

From week 2, every prompt change, retrieval-index update, and threshold calibration is gated by the eval harness running against this test set. Improvements that beat the incumbent across enough metric slices get promoted; changes that look impressive on one slice but regress on another are flagged for review. By the end of Build, the test set has grown to 600-1000 cases, the workflow has been through 15-25 eval cycles, and biotechnology leadership has empirical evidence that the system performs on their data, not on a vendor's demo.

This is the practice most biotechnology AI projects skip because it looks like overhead in the first three weeks. It is the practice that determines whether the workflow survives the third quarter of Run, which is why we treat it as the foundation of Build rather than an afterthought.

If you have ever shipped a non-trivial production system you know the first 30 days are make-or-break. For finance back office in biotechnology, the make-or-break decisions are: what does the labelled test set look like, what is in scope for the integration against ELN, where does the automation boundary sit, and how is the reviewer queue UX going to feel to your operator team. We answer all four in the first two weeks.

Labelled test set: 200 cases minimum by end of week 2, signed off by the engagement sponsor, covering routine, exceptional, ambiguous, and adversarial. Integration scope: documented and bounded by end of week 1, with the data-access plan reviewed by your engineering team. Automation boundary: drawn deliberately in week 2 — full automation lane, drafted-with-review lane, reserved-to-human lane — with confidence thresholds calibrated against the test set. Reviewer UX: prototyped in week 2 with two of your senior operators in the loop, iterated through week 3.

From day 30, the Build sprint shifts to widening the envelope. The decisions made in the first month are the ones that shape the next 12 months of operating the workflow — which is why we resist the temptation to skip ahead to the model layer before the test set and the reviewer UX have been earned.